학술논문
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up
Document Type
Article
Author
Source
In International Immunopharmacology 15 June 2024 134
Subject
Language
ISSN
1567-5769